BCAL Diagnostics Limited (BDX) Price & Analysis

Compare

7 Followers

BDX Stock Chart & Stats

AU$0.10

>-AU$0.01(-2.06%)

At close: Jan 09 4:00 PM EST

AU$0.10

>-AU$0.01(-2.06%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.16

Previous CloseN/A

Volume98.04K

Average Volume (3M)421.90K

Market Cap

AU$44.24M

Enterprise ValueAU$40.93M

Total Cash (Recent Filing)AU$3.33M

Total Debt (Recent Filing)AU$3.78M

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding368,683,300

10 Day Avg. Volume534,308

30 Day Avg. Volume421,904

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)3.64

Price to Sales (P/S)1047.06

P/FCF Ratio-3.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet HealthModerate leverage (debt-to-equity 0.38) and a 62.77% equity ratio provide financial flexibility during lengthy R&D and commercialization phases. Lower relative debt reduces near-term refinancing pressure, helping fund trials or partnerships without excessive interest burdens while pursuing validation and market entry.

Specialized Diagnostics FocusBCAL’s focus on blood-based breast cancer diagnostics targets a structural, high-demand healthcare niche. Proprietary assays and related IP can create durable competitive advantages and recurring laboratory revenue if clinical validation and commercialization succeed, making partnerships and licensing logical scaling paths.

Relative Free Cash Flow AbilityDespite negative operating cash flow overall, a positive free cash flow to net income ratio (1.13) indicates some capacity to convert activities into cash relative to reported losses. This suggests pockets of cash generation that can modestly extend runway while management works to stabilize revenues or secure strategic funding.

Bears Say

Revenue Collapse & MarginsA near-total revenue collapse (-99.16%) combined with a deeply negative net margin (-334.66%) signals material loss of sales and severe unprofitability. This undermines operating leverage, cripples reinvestment capacity for trials or commercialization, and heightens existential risk without a credible, durable revenue recovery plan.

Negative Cash GenerationPersistent negative operating and free cash flows, plus declining free cash flow growth (-14.23%), mean the company is burning cash to operate. Continued cash outflows force reliance on external financing, increasing dilution or refinancing risk and constraining the ability to invest consistently in validation, regulatory, and commercialization activities.

Very Poor Returns On EquityAn ROE of -116.40% indicates the company is destroying shareholder capital rather than generating returns. This level of negative profitability undermines investor confidence, makes fresh equity harder to raise on favorable terms, and highlights deep operational inefficiencies that must be rectified for long-term viability.

BCAL Diagnostics Limited News

BCAL Diagnostics Issues New Shares to Service Provider Under Cleansing Notice

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has issued 615,651 new...

4d ago

BDX

BCAL Diagnostics Issues Shares to Settle Service Provider Invoice

BCAL Diagnostics Limited ( ($AU:BDX) ) has shared an update. BCAL Diagnostics has applied to the ASX for...

4d ago

BDX

BCAL Director Jayne Shaw Increases Shareholding via On-Market Purchase

An update from BCAL Diagnostics Limited ( ($AU:BDX) ) is now available. BCAL Diagnostics has disclosed a change...

18d ago

BDX

BCAL Diagnostics Accelerates Commercial Rollout of Cancer Blood Tests and Targets Broader Market for BREASTESTplus

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has commenced the commercial...

1M ago

BDX

BCAL Diagnostics Ramps Up Cancer Test Launches as Clinical Data and Funding Strengthen Growth Plans

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has completed preparations for...

2M ago

BDX

BCAL Diagnostics to Launch Nationwide Cancer Detection Tests in Australia

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics Limited has announced the launch of...

3M ago

BDX

BCAL Diagnostics Launches Groundbreaking Breast Cancer Detection Test

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics Limited has achieved a significant milestone...

3M ago

BDX

BCAL Diagnostics Secures $2.5 Million R&D Tax Rebate for Cancer Detection Advancements

The latest announcement is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics Limited has received approximately...

3M ago

BDX

BCAL Diagnostics Director Increases Stake in Company

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics Limited has announced a change in...

4M ago

BDX

BCAL Diagnostics Schedules Annual General Meeting for November 2025

BCAL Diagnostics Limited ( ($AU:BDX) ) has shared an announcement. BCAL Diagnostics Limited has announced its Annual General...

4M ago

BDX

BDX FAQ

What was BCAL Diagnostics Limited’s price range in the past 12 months?

BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.

What is BCAL Diagnostics Limited’s market cap?

BCAL Diagnostics Limited’s market cap is AU$44.24M.

When is BCAL Diagnostics Limited’s upcoming earnings report date?

BCAL Diagnostics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 176 days.

How were BCAL Diagnostics Limited’s earnings last quarter?

BCAL Diagnostics Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.

Is BCAL Diagnostics Limited overvalued?

According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BCAL Diagnostics Limited pay dividends?

BCAL Diagnostics Limited does not currently pay dividends.

What is BCAL Diagnostics Limited’s EPS estimate?

BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BCAL Diagnostics Limited have?

BCAL Diagnostics Limited has 368,683,300 shares outstanding.

What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?

BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.

Which hedge fund is a major shareholder of BCAL Diagnostics Limited?

Currently, no hedge funds are holding shares in AU:BDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BCAL Diagnostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-164.22%

Trailing 12-Months

Asset Growth

-37.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BCAL Diagnostics Limited

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.